NSEPress Release (Revised)2d ago · 12 Oct 2026, 02:47 pm
Press Release (Revised)
Wanbury Limited · WANBURY
✦ AI Summary▲ PositiveProduct Launch
Wanbury Limited's subsidiary Wanbury Skin Health Limited has launched its berrysoft baby product range across multiple states in India, marking a strategic entry into the Paediatric Dermatology segment.
Analysis Scores
Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment9/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Wanbury Limited has informed the Exchange regarding a revised press release dated October 12, 2026, titled "Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoft baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.".
Attachments (1)
📄pdf
Download →
WANBURY_12102026144552_PressRelease.pdf
View document text
Wanbury Limited
Regd. Office: BSEL Tech Park, B-Wing, 10th
Floor, Sector-30A, Opp. Vashi Railway
Station, Vashi, Navi Mumbai 400703
Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email: info@wanbury.com
October 12, 2026
Website: www.wanbury.com
BSE Limited National Stock Exchange of India Ltd,
PJ. Towers, Exchange Plaza,
Dalal Street Bandra Kurla Complex,
Mumbai – 400 001. Bandra (East), Mumbai -400 051.
Script Code: 524212 Script Code: WANBURY
Dear Sir/Madam,
Sub.: Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its
berrysoft™ baby Product Range Across Multiple States in India, Marks Strategic
Entry in The Paediatric Dermatology Segment.
Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches Its berrysoft™
baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric
Dermatology Segment.
This is for your information and record & kindly ignore the previous press release.
Thanking you.
Yours faithfully,
For Wanbury Limited
Jitendra J. Gandhi
Company Secretary
Encl.: a/a
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited)
Launches Its berrysoft™ baby Product Range Across Multiple States in
India, Marks Strategic Entry in The Paediatric Dermatology Segment
Wanbury Limited, a pharmaceutical company with a global API presence and
domestic branded formulations portfolio, today announced the launch of its
berrysoft™ baby product range across multiple states in India, through its
subsidiary Wanbury Skin Health Limited.
The company has received GST registration in 5 states including Maharashtra, Delhi
and Karnataka with three more in pipeline. The company also has received CFA Drug
Licenses in Mumbai, Jaipur, Patna and Ambala with four more in pipeline.
The berrysoft™ baby range has been developed to address everyday baby skincare
and hygiene needs, with a portfolio comprising Gentle Bathing Bar, Gentle Body
Wash, Foam Shampoo, Syndet Handwash already launched and Moisturising Lotion,
Diaper Rash Cream, and Moisturising Cream in pipeline. The range features dedicated
formulations for different aspects of a baby's daily cleansing, moisturisation and
skincare routine.
The launch represents Wanbury Skin Health Limited’s strategic entry in the Paediatric
Dermatology segment, leveraging the company's existing relationships with
paediatricians (doctors specialized in children practice). Through cross-selling to its
established customer base, where Wanbury Limited already markets cold and cough
products, the company aims to extend its engagement with paediatricians and
broaden its presence in the paediatric healthcare segment. Wanbury Skin Health
Limited will also focus on building relationships with dermatologists to strengthen its
presence and drive growth in the dermatology segment.
The initiative reflects Wanbury Limited’s focus on expanding its overall healthcare
portfolio through its various subsidiaries, including Wanbury Skin Health Limited,
which focuses on dermatology solutions for children and adults. By leveraging
established market relationships, the company aims to drive growth in
complementary product categories and strengthen its presence across relevant
healthcare segments.
The multi-state launch marks an important milestone in Wanbury Limited’s growth
strategy, combining portfolio diversification with deeper engagement across its
existing healthcare professional network. The company will continue to explore
opportunities to broaden its product portfolio and strengthen its presence across
relevant healthcare categories.